Proteomics International has signed a license agreement for the sale of the PromarkerD predictive test for diabetic kidney disease in Chile. Deal expands a long-standing partnership with biotechnology company Omics Global Solutions. In Chile, 1.7 million adults, or 12.7% of the adult population, lives with diabetes. Omics now targeting other markets in Central and South America.